The Billion Dollar Molecule - Barry Werth

The Billion Dollar Molecule

Barry Werth

出版时间

1995-03-01

ISBN

9780671510572

评分

★★★★★
书籍介绍

Join journalist Barry Werth as he pulls back the curtain on Vertex, a start-up pharmaceutical company, and witness firsthand the intense drama being played out in the pioneering and hugely profitable field of drug research. Founded by Joshua Boger, a dynamic Harvard- and Merck-trained scientific whiz kid, Vertex is dedicated to designing-- atom by atom-- both a new life-saving immunosuppressant drug, and a drug to combat the virus that causes AIDS. You will be hooked from start to finish, as you go from the labs, where obsessive, fiercely competitive scientists struggle for a breakthrough, to Wall Street, where the wheeling and dealing takes on a life of its own, as Boger courts investors and finally decides to take Vertex public. Here is a fascinating no-holds-barred account of the business of science, which includes an updated epilogue about the most recent developments in the quest for a drug to cure AIDS.

Barry Werth is an award-winning journalist whose articles have appeared in such publications as The New York Times, Washington Monthly, and GQ, where he is a writer-at-large. Currently at work on an expose about doctors and lawyers, he lives in Northampton, Massachusetts.

用户评论
吹爆!从理解行业的角度,个人觉得吊打Bad Blood。几条主线都非常清晰:一是研发chase,包括医药公司之间,以及与大学实验室的惊心动魄的竞争;二是初创医药公司寻求融资,包括商业合作和IPO,非常有趣;三是公司内部的人物和管理,包括科研的艰辛,商业和科学的妥协,科学家之间的交往和嫉妒。信息量大,没有水分,无论科学还是商业方面都很专业,而且似乎都是insider的洞察,看着像是初创医药企业的微缩版百科全书。这部英文版读起来比较累,中文翻译似乎不错,还是可以读中文版吧。
假期业务缓慢,写文档写累了,百无聊赖想看看商业书籍,学习学习自己所在的领域。看完了蛮失望的。作者的写作技巧很好,写出了充分调动读者情感的一出商战大戏。但是对于药物研发和商业谈判的了解,怎么说,写出了一场好戏,但是日常商业运作90%跟好戏或者坏戏无关。所以我在想我为什么要读这些书,不过还借了两本类似的无聊先看看吧。。。。
第二遍读完,开始读懂一些了。
采访驱动依然有问题,依然需要加入excel和ppt,但整个故事精彩了很多,特别是支线
不只一个医药的分析师给我介绍这本书了。近距离展示新药开发路途中的惊心动魄的历程。最后的最后药还是没研发出来。。。可能也是想告诉我们连公司自己都不知道的事情,你华尔街就别指望看懂这了。
simply breathtaking
该电影简介由豆瓣网专职人员撰写或者由影片官方提供,版权属于豆瓣网,未经许可不得转载或使用整体或任何部分的内容。 Join journalist Barry Werth as he pulls back the curtain on Vertex, a start-up pharmaceutical company, and witness firsthand the intense drama being played out in the pioneering and hugely profitable field of drug research. Founded by Joshua Boger, a dynamic Harvard- and Merck-trained
收藏